Skip to main content

Research News

  • Brain activity during sleep differs in young people with genetic risk of psychiatric disorders

    Young people living with a genetic alteration that increases the risk of psychiatric disorders have markedly different brain activity during sleep, a study led by researchers from the Universities of Bristol and Cardiff published today in eLife shows.

    The brain activity patterns during sleep shed light on the neurobiology behind a genetic condition called 22q11.2 Deletion Syndrome (22q11.2DS) and could be used as a biomarker to detect the onset of neuropsychiatric disorders in people with 22q11.2DS.

  • First vaccine for cervical cancer to launch soon in India

    Soon India will get its first made in India vaccine against cervical cancer which is developed by Serum Institute of India (SII) and the Department of Biotechnology (DBT). The daid vaccine is Quadrivalent Human Papillomavirus vaccine (qHPV).

  • Zydus initiates Phase IV clinical trial for Desidustat

    Zydus Lifesciences initiates Phase IV clinical trial for Desidustat in patients with Chronic Kidney Disease (CKD) induced anemia.

    Desidustat sold under a brand name Oxemia which is a prescription drug approved in India for patients with Chronic Kidney Disease (CKD) induced anemia, and can be taken only under the advice and guidance of a Nephrologist or an internal medicine specialist.

  • Artificial Intelligence Improves Treatment in Women with Heart Attacks

    Heart attacks in women are more likely to be fatal than in men. The reasons are differences in age and in comorbidity burden which makes risk assessment in women a challenge. Researchers at the University of Zurich have now developed a novel artificial-intelligence-based risk score that improves personalized care for female patients with heart attacks.

  • Sugar Disrupts Microbiome, Eliminates Protection Against Obesity and Diabetes

    A study of mice found that dietary sugar alters the gut microbiome, setting off a chain of events that leads to metabolic disease, pre-diabetes, and weight gain.

    The findings, published today in Cell(link is external and opens in a new window), suggest that diet matters, but an optimal microbiome is equally important for the prevention of metabolic syndrome, diabetes, and obesity.
    Diet alters microbiome.

  • Polypill reduces cardiovascular mortality by 33% in patients treated after a heart attack

    A three-drug medication known as a polypill, developed by the Spanish National Center for Cardiovascular Research (CNIC) and Ferrer, is effective in preventing secondary adverse cardiovascular events in people who have previously had a heart attack, reducing cardiovascular mortality by 33 percent in this patient population.  These are findings from the SECURE trial led by Valentin Fuster, MD, PhD, Director of Mount Sinai Heart and Physician-in-Chief of The Mount Sinai Hospital, and General Director of CNIC.

  • First African medicine to prevent malaria approved by WHO

    Local supply of a medicine used to prevent malaria across Africa received a boost recently, as the World Health Organization (WHO) issued a quality certification to the first African manufacturer of a key antimalarial drug used to prevent infection in pregnant women and children. Called pre- qualification, this certification will enable Kenyan manufacturer Universal Corporation Ltd (UCL) to support regional efforts to combat malaria through local production of high-quality sulfadoxine-pyrimethamine (SP).

  • Microscopy reveals mechanism behind new CRISPR tool

    New research from Cornell offers insights into a line of CRISPR systems, which could lead to promising antiviral and tissue engineering tools in animal and plants.

    The research by Ailong Ke, the Robert J. Appel Professor of molecular biology and genetics in the College of Arts and Sciences, and Stan J.J. Brouns at Delft University of Technology in the Netherlands, focuses on a newly discovered CRISPR RNA-guided Caspase system, otherwise known as Craspase.

  • Universal Flu Vaccine Protects Against Variants of Both Influenza A and B Viruses : Researcher

    A new universal flu vaccine protects against diverse variants of both influenza A and B viruses in mice, according to a new study by researchers in the Institute for Biomedical Sciences at Georgia State University.

    The researchers designed a single, universal influenza vaccine candidate with key cross-protective, less variable parts of the influenza A and B viruses: multi-neuraminidase protein subtypes known to be major antiviral drug targets and the universally conserved M2 ectodomain protein.

  • Nirmatrelvir effective in elder COVID-19 patients

    Israel based scientists found out that the rates of hospitalization and death due to COVID-19 were significantly lower among those who received nirmatrelvir in patients 65 years of age or older.

    At the beginning of the surge of the omicron variant in January 2022, the Israeli authorities decided to pursue two lines of defense to protect the vulnerable and high-risk populations from severe Covid-19: a second booster dose and antiviral therapy.

Subscribe to Research News